IDEXX Laboratories, Inc.IDXX
Price$517.75Intrinsic value$520.010% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $520.01median of 6 methods · middle span $490-$617based on filings through 30 Jun 2026
Market Price $517.75Price as of 1 Oct 2026
Margin of Safety +0.4%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 9.1% (near-term consensus, capped) · years 2–5: 14.3%/yr (balance of the path).13.3% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 614.1%Yr 713.9%Yr 813.7%Yr 913.5%Yr 1013.3%
14.3% → 13.3%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1112.2%Yr 1211.2%Yr 1310.2%Yr 149.2%Yr 158.1%Yr 167.1%Yr 176.1%Yr 185.1%Yr 194.0%Yr 203.0%
13.3% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)17.4%
Discount rate (cost of equity) 11.0%
Volatility vs market (adjusted beta)1.35

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetIDEXX Laboratories, Inc.IDXXHealth Care
Valuation
P/E36.4×
P/S8.8×
P/B24.9×
EV / Revenue8.8×
EV / EBITDA—
Profitability
Gross margin59.8%
Operating margin32.7%
Net margin25.0%
FCF margin27.5%
Returns
ROE70.7%
ROA33.1%
ROIC61.1%
Growth
Revenue growth (YoY)16.8%
5-yr fwd EPS growth13.3%
Financial strength
Debt / Equity0.28×
Current ratio1.17×
Altman Z-Score19.1
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.